Sinovac Biotech Ltd (SVA) stock

SVANasdaqPharmaceutical PreparationsFiscal year ends December 31

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Jun 5, 2026Score 6/30

$6.47+0.00 (0.00%)

Close on Nov 13, 2026Market cap $464.94MP/E –Yield 850.08%

Sinovac Biotech EV/EBITDA

EV/EBITDA is enterprise value divided by EBITDA over the trailing twelve months.

Sinovac Biotech's EV/EBITDA was 7.2× on Jan 29, 2021, against 7.2× a year earlier. Over the last 5 years it ranged from 6.5× to 895.3×, with a median of 8.0×.

EV/EBITDA at the end of each year

Period	Period end	Value	Change (pts)
2021	Jan 29, 2021	7.2×	+0.0
2020	Dec 31, 2020	7.2×	+0.0
2019	Dec 31, 2019	7.2×	+0.0
2018	Dec 31, 2018	7.2×	−844.0
2017	Dec 29, 2017	851.2×	+768.1
2016	Dec 30, 2016	83.1×	−71.8
2015	Dec 31, 2015	154.9×	+133.2
2014	Dec 31, 2014	21.6×	+8.8
2013	Feb 28, 2013	12.9×	+2.7
2012	Dec 31, 2012	10.1×	+6.4
2011	Feb 28, 2011	3.7×	+1.0
2010	Dec 31, 2010	2.7×	–

Where these numbers come from

Parsed from the XBRL in Sinovac Biotech's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is SVA.

Compare: SVA vs HCM · SVA vs ZLAB · SVA vs AAPG · SVA vs NVAX · SVA vs KMDA

Revenue growth6.8% · median -2.1%

Gross margin67.9% · median 54.7%

Operating margin-127.0% · median -42.1%

Company	Revenue	Growth
ZLAB	$441.73M	+0.0%
NVAX	$411.65M	-61.3%
SVA	$386.01M	+6.8%
HCM	$204.89M	-4.3%
KMDA	$191.85M	+13.2%
AAPG	–	–

Company

Exchange: Nasdaq
Industry: Pharmaceutical Preparations
Fiscal year ends: December 31
Employees: 2,602
Held by institutions: 14.6%
Auditor: Zhonghua Certified Public Accountants LLP
SEC CIK: 1084201

Advertisement
300 × 250

See a number that looks wrong?

Sinovac Biotech EV/EBITDA

EV/EBITDA at the end of each year

More Sinovac Biotech figures